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Important questions remain about whether CETP inhibition, despite its positive effects on HDL-C levels, will reduce ASCVD. One theoretical concern is that CETP inhibition could slow the rate of reverse cholesterol transport (RCT), the process by which macrophage cholesterol in the vessel wall is returned to the liver for excretion. In studies in humans, radiolabeled cholesteryl esters that originated in HDL ultimately appeared in the bile primarily after their transfer (presumably mediated by CETP) to apolipoprotein B-containing lipoproteins, 7 which suggests that CETP might play an important physiological role in RCT. Ultimately, randomized controlled trials of CETP inhibitors will definitively address their effect on atherosclerosis and cardiovascular events. In the meantime, observational studies in humans have the potential to provide important insights into this critical question. Such observational studies include careful assessment of cardiovascular risk in CETP-deficient subjects (both homozygous and heterozygous), as well as studies of the association of CETP polymorphisms and plasma CETP levels with cardiovascular outcomes.
Observational Studies of the Relationship Between CETP and Coronary Artery Disease
It has been difficult to establish a consensus about the prevalence of cardiovascular disease in the relatively small number of homozygous CETP-deficient subjects (who are largely limited to Japan) compared with the normal Japanese population. For example, in one report of 29 homozygotes or compound heterozygotes for CETP deficiency, only one had clinical coronary heart disease (CHD), and this patient also was found to have substantially reduced hepatic lipase activity. 8 Therefore, most efforts to assess the relationship between CETP deficiency and CHD have focused on heterozygotes. In a large population-based study in Japan, CETP gene mutations were identified in 24% of men and more than 30% of women who had HDL cholesterol levels Ͼ80 mg/dL, a phenotype that was associated with a low risk of CHD, 9 but this does not directly indicate that the CETP-heterozygous state is protective. A recent prospective analysis from the Honolulu Heart Study suggested that the risk of CHD might be lower in CETP-deficient heterozygotes, but the trend was not statistically significant. 10 Therefore, the relationship of genetic homozygous or heterozygous CETP deficiency to cardiovascular risk remains unclear.
Common single-nucleotide polymorphisms (SNPs) in the human CETP gene also have been investigated for their association with cardiovascular disease. Subjects carrying the B2 allele of the Taq1B SNP in intron 1 had lower CETP levels, higher HDL-C levels, and reduced risk of CHD in the Framingham Offspring Study. 11 The I405V SNP has been associated with increased HDL-C and increased risk of CHD in women in the Copenhagen City Heart Study. 12 A formal meta-analysis of the Taq1B and I405V SNPs revealed that the Taq1B B2B2 genotype possibly is associated with reduced cardiovascular disease but provided no evidence that the I405V was associated with cardiovascular disease. 13 Two additional CETP-coding SNPs, A373P and R451Q, are in almost complete linkage disequilibrium. In the Copenhagen City Heart Study, carriers of the rarer 373P/451Q haplotype had reduced levels of HDL-C and a lower CHD risk. 12 A few common promoter SNPs have been studied, including a Ϫ629A/C and a variable-number tandem repeat (VNTR) 1946 upstream of the transcription initiation site, and although both are associated with variation in CETP mass and HDL-C levels, 13, 14 they have not been shown to be associated with CHD. Thus, the existing data on common genetic variations in CETP are variable and do not definitively resolve the relationship of CETP and ASCVD. Finally, studies of the association of plasma CETP levels with cardiovascular disease and outcomes have the potential to provide important insight into this issue. There is a surprising dearth of epidemiological data, however, on the association of plasma CETP mass or activity levels with cardiovascular disease. Patients with higher CETP mass had faster progression of angiographic coronary artery disease (CAD) 15 and faster progression of carotid intimal-medial thickness. 16 In a small case-control study (nϭ82 cases) primarily focused on CETP genetic variation, Blankenberg et al 17 found no difference between CETP activity levels in cases and controls. A small study (nϭ110) in Japanese patients undergoing angiography found no correlation of CETP mass levels with extent of coronary atherosclerosis. 18 Another small case-control study (nϭ204) in Chinese found that subjects with myocardial infarction or stroke had higher CETP mass and activity than did controls. 19 Because of the limited and mixed results of studies of the association of CETP levels and cardiovascular disease, the article by Boekholdt et al 20 in this issue of Circulation provides important new information. Data are presented from a nested case-control study from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk cohort study, a large prospective study initiated in the mid-1900s. Seven hundred fifty-five originally healthy individuals who developed fatal or nonfatal CAD during follow-up were identified as cases and matched to 1400 controls who remained free of CAD. CETP mass levels were measured in baseline plasma samples by using a commercial ELISA and were assessed for their relationship to CAD. Within the entire cohort, CETP levels were inversely related to HDL-C levels (and directly related to LDL-C levels). Although CETP levels were slightly higher in cases, this difference was not statistically significant. However, subjects in the highest quintile of CETP mass had a nearly 1.5-fold increased risk of future CAD compared with those in the lowest quintile after adjustment for several cardiovascular risk factors but not lipids. It is unfortunate that the results after adjustment for plasma lipids are not provided, but given the strong association of CETP levels with both HDL-C and LDL-C levels, it seems likely that the association of CETP levels with CAD would have been markedly attenuated after adjustment for lipids. Provocatively, a stratified analysis in subjects above or below the median (nonfasting) triglyceride (TG) level showed no association of CETP levels and CAD in those below the TG median but a significant positive association for those above the TG median. This relationship disappeared after adjusting for HDL-C levels, which suggests that if CETP influenced the risk of CAD, it did so by modulating HDL metabolism.
The article by Boekholdt et al 20 provides the first prospective epidemiological data on the association of CETP levels and cardiovascular events and has potentially important implications for the development of CETP inhibitors. Given the controversy and uncertainty about cardiovascular disease in CETP-deficient subjects, this prospective study provides assurance that lower levels of CETP mass are in fact associated with both increased HDL-C levels and reduced CAD risk. Therefore, it supports the concept of CETP inhibition not only to raise HDL-C levels but to reduce CAD risk. Interestingly, however, the association of CETP levels and CAD appeared to be confined to those persons with elevated nonfasting TG levels. This is biologically plausible because CETP exchanges cholesteryl esters from HDL to apolipoprotein B-containing lipoproteins in exchange for TGs, and its activity is determined in part by the number of TG-rich lipoproteins. Therefore, for a given amount of CETP mass in plasma, the greater the number of TG-rich lipoproteins, the greater the CETP-mediated transfer of lipids. The implication of this observation is that CETP inhibition may be more effective in reducing cardiovascular risk in patients with elevated TG levels. It will be interesting to determine whether CETP inhibitors have differential effects on lipid levels, atherosclerosis, and clinical events in persons with elevated compared with normal TG levels.
Assessing the Benefits of HDL-Raising Interventions
The complex relationship of CETP with lipoprotein metabolism and atherosclerosis provides a fascinating opportunity to address the potentially important differences between plasma HDL-C concentrations and HDL function with regard to atherosclerosis. Although it is widely accepted that HDL directly protects against atherosclerosis, the mechanisms by which HDL exerts its protective effect remain uncertain, and the biomarkers and methods for measuring these effects have yet to be developed and validated. For example, the rate of RCT from vessel wall to liver is likely to be more important than the plasma levels of HDL-C, and therefore validated measures of the rate of RCT in humans are sorely needed. Furthermore, HDL has been shown in vitro to have a variety of other properties, such as antiinflammatory, antioxidative, antithrombotic, and nitric oxide-promoting effects, but whether these are relevant in humans in vivo and how best to assess these effects after administration of HDL-raising drugs remain unknown. CETP inhibitors will provide the opportunity to test whether this particular mechanism of HDL-raising has beneficial effects on RCT and other putative HDL functions that ultimately may result in reduced atherosclerotic vascular disease.
In summary, although pharmacological inhibition of CETP in humans clearly increases HDL-C levels, its effect on ASCVD is far from established. Observational studies of the relationships between CETP, lipoprotein metabolism, and ASCVD, such as the study by Boekholdt et al, 20 will continue to inform this important issue. Experimental medicine studies of the effects of CETP inhibitors on cholesterol flux and other potential HDL functional effects will constitute a critical component of the understanding of this mechanism of HDLraising and its biological effects. Ultimately, randomized controlled clinical trials assessing the impact on atherosclerosis will determine whether CETP inhibition will become a new tool in the fight against ASCVD.
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